GlassScriptPhysician profile
Sara Lynn Bell
NPI 1245705896
$5,545.16
in general payments reported to CMS, 2019-2025
44 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $490 · 2022: $1,034 · 2023: $1,210 · 2024: $950 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,693 · Education: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,693.38 |
| Education | $328.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $648.59 | 2021-2025 | Rybrevant, Imbruvica, Tecvayli |
| Novartis Pharmaceuticals Corporation | $416.89 | 2021-2025 | Kisqali, Piqray |
| Astrazeneca Pharmaceuticals LP | $376.96 | 2022-2025 | Calquence, Lynparza, Tagrisso |
| Merck Sharp & Dohme LLC | $375.37 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Seagen INC. | $295.16 | 2022-2025 | Tukysa, Adcetris |
| Daiichi Sankyo INC. | $294.84 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $268.35 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $235.00 | 2022-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $234.12 | 2023-2025 | Trodelvy |
| Celgene Corporation | $226.15 | 2022-2025 | Reblozyl, Opdualag, Breyanzi |
| Incyte Corporation | $211.88 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $193.02 | 2022-2025 | |
| Glaxosmithkline, LLC. | $166.13 | 2021-2025 | Ojjaara, Blenrep, Shingrix |
| Amgen INC. | $165.34 | 2021-2023 | Kyprolis, Lumakras, Nplate |
| Abbvie INC. | $130.02 | 2024-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.